ADAM17 and kidney disorder: Furthermore, we now show that the beneficial anti-inflammatory effects of VDRAs such as paricalcitol in renal disease may be explained by inhibition of Aldo-mediated proinflammatory factors overexpression through modulation of ADAM17/TGF-α/EGFR signalling axis and dampening of downstream mechanisms, including ERK and STAT-1 activation.